The short answer
Alpha-MSH has two functionally separable activities: pigmentation and anti-inflammation. Isolating the C-terminal tripeptide keeps the second without the first, which is the entire rationale for KPV existing as a distinct research compound.
Key facts
- Parent
- alpha-MSH, 13 residues, 1,664.9 Da
- Fragment
- KPV, 3 residues, 342.43 Da
- Discarded
- Melanocortin receptor engagement
- Retained
- Reported anti-inflammatory activity
- Additional change
- Size permits intracellular access
- Guaranteed?
- No, fragments are different molecules
The clean case for a fragment
Fragment isolation is most defensible when a parent has two separable functions and only one is wanted. Alpha-MSH is close to that ideal: pigmentation runs through melanocortin receptor engagement by the core sequence, and anti-inflammatory activity localises to the C-terminus. Taking the C-terminus alone is a targeted separation rather than a hopeful truncation.
What changes beyond losing a function
Size, dramatically. Going from 1,665 Da to 342 Da is not a minor trim. It is a fivefold reduction that changes what the molecule can physically do. The parent cannot cross membranes; the fragment plausibly can. So the fragment is not simply the parent minus pigmentation; it is a molecule with different access to different compartments.
Research material referenced
KPV 10mg, third-party HPLC tested
Why that cuts both ways
A fragment small enough to enter cells might act by a mechanism the parent never used, which would mean the anti-inflammatory activity of KPV and of alpha-MSH are not necessarily the same phenomenon. That possibility is rarely acknowledged, and it means parent-fragment read-across should be applied cautiously in both directions.
How this compares with the library's other fragments
The 7-residue LKKTETQ fragment that some papers call TB-500 takes an internal motif from thymosin beta-4, while most findings cited under the TB-500 name used the full protein. Modified GRF (1-29) takes GHRH's active fragment and retains full agonist activity. KPV sits between: the separation is well motivated, and the size change is large enough that the fragment is a different kind of molecule from its parent.
What the delivery work implies
The 2017 Molecular Therapy paper on targeted oral delivery indicates that reaching the intended tissue was the practical obstacle, not activity. A compound needing a delivery vehicle is one whose free form does not arrive where it is wanted. That is a real limitation, and one the fragment inherited from being very small and rapidly cleared.
Frequently asked questions
Why not just use alpha-MSH?
It drives pigmentation through melanocortin receptors, which is a confound for anti-inflammatory research. The fragment separates the two activities.
Does KPV work the same way as its parent?
Not necessarily. At a fifth of the mass it may access compartments alpha-MSH cannot, so the mechanisms may differ.
What limits KPV in practice?
Delivery. The published targeted-delivery work indicates the free tripeptide's arrival at intended tissue was the obstacle.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBrzoska T et al., Terminal signal: anti-inflammatory effects of alpha-MSH. Adv Exp Med Biol 2010 (PMID 21222263)pubmed.ncbi.nlm.nih.gov
- PubMedXiao B et al., Orally targeted delivery of tripeptide KPV. Mol Ther 2017 (PMID 28143741)pubmed.ncbi.nlm.nih.gov
- PubMedLuger TA et al. Ann N Y Acad Sci 2003 (PMID 12851308)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- What the Colitis Models ReportedKannengiesser 2008 reported anti-inflammatory potential in murine colitis. What a disease model establishes, and the gap before any clinical claim.
- KPV in the Published LiteratureAbout 34 indexed records, mostly murine and cell culture. How to search a compound whose abbreviation collides with an unrelated chemical.
- KPV Regulatory StatusNo marketing authorisation anywhere. Why an anti-inflammatory literature makes the claims boundary particularly easy to cross.
- The Transporter That Explains the TripeptideKPV is a substrate for PepT1, the intestinal di- and tripeptide transporter. That single fact organises almost everything published about this molecule.
- Delete the Transporter and the Effect DisappearsIn PepT1 knockout mice, KPV produced none of the effect it produced in wild-type animals. That is a stronger mechanistic test than any dose-response curve.